[["treatment options for advanced metastatic thyroid cancer patients", "are", "limited"], ["vemurafenib", "is", "a BRAFV600E inhibitor"], ["vemurafenib", "has shown", "promise in clinical trials"], ["cellular resistance", "occurs", "with vemurafenib"], ["combination therapy", "is a clinical need", "to avoid resistance"], ["combination treatment", "was examined", "with vemurafenib and mTOR inhibitors"], ["mTOR inhibitors", "include", "metformin and rapamycin"], ["cellular viability and apoptosis", "were analyzed", "in thyroid cell lines"], ["combination of vemurafenib and metformin", "decreased", "cell viability"], ["combination of vemurafenib and metformin", "increased", "apoptosis in BCPAP and 8505c cells"], ["this combination", "was found to be", "active in vemurafenib-resistant BCPAP cells"], ["changes in expression of signaling molecules", "were observed", "such as decreased mTOR expression"], ["decreased mTOR expression", "was observed in", "BCPAP cells"], ["enhanced inhibition of phospho-MAPK", "was observed in", "resistant BCPAP and 8505c cells"], ["combination of vemurafenib and rapamycin", "amplified", "cell death in BCPAP cells"], ["combination of BRAFV600E and mTOR inhibition", "forms", "the basis of a treatment regimen"], ["metformin or rapamycin adjuvant treatment", "may provide", "clinical benefits with minimal side effects"], ["adjuvant treatment", "is for", "BRAFV600E-positive advanced thyroid cancer patients treated with vemurafenib"]]